Splitgill Mushroom

Metadata

Regulatory Status

Japan (Pharmaceutical Approval)

SPG (sizofiran, brand name Sonifilan) was approved as a pharmaceutical by the Japanese Ministry of Health in 1986 for cervical cancer adjunctive immunotherapy.

• Product: Sonifilan (sizofiran/SPG), manufactured by Kaken Pharmaceutical Co., Ltd.
• Approval: Biological response modifier for cancer immunotherapy
• Indication: Adjunctive immunotherapy for cervical cancer stages II-III, administered by intralesional injection alongside radiation therapy
• Route: Intralesional/intratumoral injection (NOT oral)
• Dosage: 20 mg per injection, once weekly during radiation therapy course (typically 5-10 injections)
• Status: SPG completes the trio of Japanese-approved mushroom pharmaceuticals alongside PSK (1977, Turkey Tail) and lentinan (1985, Shiitake)

China

• Not listed in the Chinese Pharmacopoeia as a medicinal species
• S. commune is consumed as food in some regions but lacks formal medicinal recognition

United States

• No pharmaceutical approval or FDA GRAS status for SPG
• S. commune supplements are available as dietary supplements under DSHEA
• No NIH-funded clinical trials of SPG or S. commune

European Union

• No Novel Food assessment
• No EMA/HMPC monograph
• S. commune fruiting bodies are consumed as food in some regions

Conditions & Indications

Primary (Strong Evidence — Pharmaceutical-Level)

• Cervical cancer adjunctive therapy — SPG administered by intralesional injection alongside radiation therapy significantly improved complete response rates and overall survival in multiple RCTs. The Okamura et al. (1989) pivotal Phase III trial (n=367) demonstrated significantly higher complete response rates in the SPG group vs. radiation alone, with the most pronounced survival benefit in stage III patients. The Okamura et al. (1986) Phase II trial showed 86.4% complete response rate in the SPG group vs. 60.7% in controls (p<0.05).

Secondary (Moderate Evidence)

• Immune modulation in cancer patients — SPG enhances NK cell activity, T-cell proliferation, and pro-inflammatory cytokine production (IL-2, IFN-gamma, IL-12) in cancer patients. Documented through serum biomarker measurements across multiple trials.
• Head and neck cancer adjunctive therapy — Shimizu et al. (1988) showed improved local control rates with SPG + radiation vs. radiation alone in head and neck cancer (n=42), supporting generalizability beyond cervical cancer.

Emerging/Preclinical

• Dendritic cell vaccination adjuvant — Roeven et al. (2018) demonstrated schizophyllan as a novel adjuvant for dendritic cell vaccination protocols, exploiting the triple-helix structure for polynucleotide delivery.
• Drug delivery platform — SPG’s triple-helix can exchange one glucan strand for a single-stranded polynucleotide (DNA/RNA), creating a polysaccharide-nucleotide complex with potential gene therapy and vaccine applications.

Mechanism of Action

Primary Mechanisms

1. Beta-glucan activation of innate immune cells via Dectin-1 receptor: SPG’s beta-1,3/1,6-glucan structure is recognized by Dectin-1 (CLEC7A), the primary beta-glucan pattern recognition receptor on macrophages and dendritic cells. The triple-helical conformation maximizes Dectin-1 receptor clustering and downstream NF-kB/MAPK signaling, producing enhanced macrophage activation compared to single-chain or random-coil glucans.

2. Complement Receptor 3 (CR3/CD11b/CD18) priming: SPG primes CR3 on NK cells and neutrophils through a two-step mechanism: (1) SPG binding to the CR3 lectin domain, (2) enhanced killing of iC3b-opsonized tumor cells. This complement-dependent antitumor mechanism is distinct from Dectin-1-mediated effects.

3. Macrophage M1 polarization in tumor microenvironment: SPG activates tumor-associated macrophages toward the M1 (pro-inflammatory, antitumor) phenotype, increasing production of ROS, NO (via iNOS), TNF-alpha, and IL-12. This M1 polarization converts immunosuppressive tumor microenvironments into immunologically active ones, synergizing with radiation therapy.

Secondary Mechanisms

4. Dendritic cell maturation and antigen presentation: SPG promotes DC maturation with upregulation of MHC class I/II, CD80, CD86, CD40, and IL-12, enhancing tumor-specific CTL priming and Th1 polarization.

5. Synergy with radiation-induced immunogenic cell death (ICD): Radiation releases DAMPs (calreticulin, HMGB1, ATP) from dying tumor cells. SPG amplifies immune responses to these DAMPs by activating local APCs, converting localized radiation into a combined local-systemic immunotherapy approach.

6. Cytokine cascade: SPG triggers coordinated production of IL-1beta, TNF-alpha, IL-12, IFN-gamma, IL-2, and GM-CSF, documented through serum cytokine measurements in cervical cancer patients.

Key Pharmacological Note: Triple-Helix Conformation

The triple-helical tertiary structure of SPG is a distinguishing biophysical feature. Three polysaccharide chains wind around each other to form a rigid rod-like triple helix (~2 nm diameter, lengths up to several micrometers). This conformation:

• Maximizes Dectin-1 receptor clustering and signaling
• Provides colloidal stability and resistance to enzymatic degradation
• Enables complexation with single-stranded polynucleotides (DNA, RNA) by strand exchange — a property exploited in drug delivery research
• Is disrupted by DMSO, strong alkali, or temperatures >135°C

SPG differs from PSK (Turkey Tail) in being a protein-free beta-glucan (no peptide moiety). SPG differs from lentinan (Shiitake) in branching pattern: beta-1,6 branches every 3 residues (vs. every 5 for lentinan), giving SPG higher branching density.

Clinical Evidence Summary

Systematic Reviews

Key Individual Trials

Key Trial Detail: Okamura et al. (1989) Pivotal Phase III

• Design: Multicenter RCT across multiple Japanese cancer centers
• Population: 367 patients with cervical cancer stages II and III undergoing radical radiation therapy
• Intervention: SPG 20 mg intralesional injection once weekly during radiation (5-10 injections) vs. radiation alone
• Results: Significantly higher complete response rate in SPG group; overall survival improved with most pronounced benefit in stage III (where baseline prognosis is poorest)
• Safety: Well-tolerated; no treatment discontinuations due to adverse events
• Significance: Formed the registration dossier for pharmaceutical approval in Japan

Evidence Limitations

• Indication concentration: Nearly all RCT evidence is in cervical cancer only (unlike PSK which spans gastric, colorectal, and lung cancer)
• Route of administration: SPG was injected intralesionally, NOT taken orally. Clinical evidence does NOT support oral S. commune supplement use
• Geographic concentration: All pivotal trials conducted in Japan; no Western RCTs
• Trial era: 1980s-1990s trials; predate current CONSORT standards and modern cervical cancer treatment (concurrent chemoradiation)
• Strain specificity: Pharmaceutical SPG from ATCC 38548 strain under GMP; commercial supplements cannot be assumed equivalent
• No head-to-head comparisons with modern immunotherapies or other mushroom BRMs
• HPV era: Trials predate HPV vaccination and modern screening, fundamentally changing cervical cancer epidemiology

Safety Profile

General Assessment

SPG has an established safety profile from pharmaceutical use in Japan since 1986 (>800 patients in controlled trials). Well-tolerated with side effects primarily related to injection route.

Special Safety Consideration: S. commune as Opportunistic Pathogen

Schizophyllum commune is unique among medicinal mushrooms as a documented opportunistic human pathogen:

• Allergic bronchopulmonary mycosis (ABPM) in immunocompromised patients
• Fungal sinusitis (immunocompromised and occasionally immunocompetent)
• Onychomycosis
• Rare CNS infections in severely immunocompromised patients
• Skin/mucosal ulcerative lesions

Important: Pharmaceutical SPG is a purified polysaccharide, not a live organism. Infections are caused by viable spores/hyphae, not purified beta-glucans. Pathogenicity is almost exclusively associated with immunocompromised states. However, handling of live cultures/unprocessed fruiting bodies warrants caution in immunocompromised individuals.

Contraindications

• Known allergy to mushrooms (Basidiomycota)
• Severe immunocompromise (opportunistic pathogen risk + immunostimulation concerns)
• Autoimmune disease (immune stimulation could exacerbate)
• Organ transplant recipients (both immunostimulatory antagonism and infection risk)
• Pregnancy and lactation (insufficient data)

Drug Interactions

• Immunosuppressants: SPG’s immunostimulatory effects may antagonize immunosuppressive therapy
• Radiation therapy: Designed synergy — enhances radiation efficacy (approved indication)
• Checkpoint inhibitors: Theoretical additive immune stimulation; no data; caution advised

Side Effects

• Common (injection): Local injection site pain, erythema, induration (10-20%); transient low-grade fever
• Uncommon: Flu-like symptoms, transient elevated CRP/ESR
• Rare: Allergic skin rash, peripheral eosinophilia

Toxicology

• Pharmaceutical-grade toxicology assessment completed for Japanese approval
• Ames test negative (non-mutagenic)
• No carcinogenicity or organ toxicity in preclinical studies
• No reproductive toxicity in animal studies (human data lacking)

Clinical Dosage

Pharmaceutical-Grade SPG (Sonifilan, Japan)

• Standard dose: 20 mg per intralesional injection, once weekly during radiation therapy
• Duration: 5-10 injections over radiation course
• Route: Intralesional injection (NOT oral)
• This is the ONLY dosage supported by Phase III RCT data
• Available only as a prescription pharmaceutical in Japan

Supplement-Grade S. commune (NO CLINICAL VALIDATION)

• No clinically validated oral dosage exists
• Typical supplement doses: 500-2000 mg/day dried fruiting body powder or extract
• Critical: oral bioavailability of intact triple-helix schizophyllan is uncertain
• Supplements CANNOT claim equivalence to pharmaceutical SPG

Critical Quality Gap

The gap between pharmaceutical SPG and supplement-grade S. commune is the widest of any medicinal mushroom:

1. Route: Injectable (pharmaceutical) vs. oral (supplement)
2. Purity: Purified beta-glucan from specific strain vs. whole-mushroom products
3. Conformation: Triple-helix may not survive processing
4. Evidence: No clinical trial has tested oral S. commune for any indication

Sources

Clinical Trial References

• Okamura K, Suzuki M, Chihara T, et al. Clinical evaluation of schizophyllan combined with irradiation in patients with cervical cancer. Cancer. 1986;58(4):865-872
• Okamura K, Hamazaki Y, Yajima A, Noda K. Adjuvant immunotherapy: two randomized controlled studies of patients with cervical cancer. Biomed Pharmacother. 1989;43(3):177-181
• Komatsu T, Okamura K, Fujiwara A, et al. Effect of sizofiran (SPG) combined with irradiation on cervical cancer. Int J Immunopharmacol. 1990;12(4):445-451
• Inoue M, Tanaka Y, Sugita N, et al. Improvement of long-term prognosis in patients with ovarian cancers by adjuvant sizofiran immunotherapy. Biotherapy. 1993;6(1):13-18
• Miyazaki K, Mizutani H, Katabuchi H, et al. Activated (HLA-DR+) T-lymphocyte subsets in cervical carcinoma and effects of radiotherapy and immunotherapy with sizofiran. Gynecol Oncol. 1995;56(3):412-420
• Shimizu Y, Hasumi K, Okudaira Y, et al. Immunotherapy of advanced gynecologic cancer patients utilizing SPG. Tohoku J Exp Med. 1988;155(4):393-398

Pharmacological References

• Yanaki T, Norisuye T, Fujita H. Triple helix of schizophyllan: chain conformation in dilute solution. Macromolecules. 1980;13(6):1462-1466
• Rau U. Schizophyllan. In: Steinbuchel A, editor. Biopolymers, Vol. 6. Wiley-VCH; 2002. p. 61-80
• Roeven MW, et al. Schizophyllan as a novel adjuvant for dendritic cell vaccination protocols. Immunotherapy. 2018;10(7):553-563
• Chowdhary A, et al. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus. Crit Rev Microbiol. 2014;40(1):30-48
• Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002;60(3):258-274

Regulatory

• Japanese Ministry of Health, Labour and Welfare. Sizofiran (Sonifilan) approval documentation, Kaken Pharmaceutical, 1986

Connections

• One of three mushroom-derived pharmaceuticals (alongside PSK from Turkey Tail and lentinan from Shiitake), all approved in Japan 1977-1986
• Beta-glucan immune activation (Dectin-1, TLR2, CR3) is shared across all three but SPG’s triple-helix and higher branching density distinguish it structurally
• SPG’s injection route makes clinical evidence least transferable to supplement context among the three pharmaceutical mushroom compounds
• Opportunistic pathogenicity is unique among medicinal mushrooms and requires explicit safety discussion
• Synergy with radiation therapy is distinctive (PSK and lentinan are combined with chemotherapy)
• Compare with Reishi — both immune-modulation category but Reishi has broader traditional and clinical evidence across multiple indications